We use cookies on this site. By browsing our site you agree to our use of cookies. Close this message Find out more

Home > School Seminar - Dr Julie Dumonceaux
More in this section Seminars

School Seminar - Dr Julie Dumonceaux

Location
BLT2
Date(s)
01/03/2017 (16:00-17:00)
Description
Picture1

FSHD

Host - Dr Jon Beauchamp

Dr Julie Dumonceaux

University College London

 

What happens when an ancient DNA retro-element gets activated and comes back to life in error?

Facio-scapulo-humeral muscular dystrophy (FSHD) and new therapeutic approaches.

FSHD is one of the most common muscular dystrophies and so far there is no curative or preventive treatment. FSHD is characterized by a loss of repressive epigenetic marks within the D4Z4 array, leading to chromatin relaxation and, when associated with a permissive chromosome 4, to the expression of the normally silenced DUX4 protein whose ORF is present in each D4Z4 repeat. DUX4 is a transcription factor resulting in a poison protein through induction of downstream genes, which may play a major role in FSHD onset/progression.

Our laboratory has been working on FSHD for years, deciphering the molecular pathways leading to FSHD onset. We have also recently developed different innovative therapeutic strategy for FSHD. The first one aims at targeting the 3’ UTR key elements of DUX4 pre-mRNA using antisense oligonucleotides to inhibit the polyadenylation and induce mRNA degradation. In the second one, a new strategy, never developed for a neuromuscular disease, was evaluated. Because DUX4 is a transcription factor, we designed DNA decoys trapping the DUX4 protein, thereby preventing its binding to genomic DNA. We established proof of principle in vitro for these therapeutic strategies capable of inhibiting DUX4 pathway.


   
 
 
 

Comment on this page

Did you find the information you were looking for? Is there a broken link or content that needs updating? Let us know so we can improve the page.

Note: If you need further information or have a question that cannot be satisfied by this page, please call our switchboard on +44 (0)1784 434455.

This window will close when you submit your comment.

Add Your Feedback
Close